Identification of Novel Mutations in HEXA Gene in Children Affected with Tay Sachs Disease from India by Mistri, Mehul et al.
Identification of Novel Mutations in HEXA Gene in
Children Affected with Tay Sachs Disease from India
Mehul Mistri
1., Parag M Tamhankar
2*
., Frenny Sheth
1, Daksha Sanghavi
2, Pratima Kondurkar
2,
Swapnil Patil
3, Susan Idicula-Thomas
3, Sarita Gupta
4, Jayesh Sheth
1*
1FRIGE Institute of Human Genetics, Ahmedabad, Gujarat, India, 2ICMR Genetic Research Center, National Institute for Research in Reproductive Health, Mumbai,
Maharashtra, India, 3Biomedical Informatics Center, National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India, 4Department of Biochemistry,
M.S. University, Vadodara, Gujarat, India
Abstract
Tay Sachs disease (TSD) is a neurodegenerative disorder due to b-hexosaminidase A deficiency caused by mutations in the
HEXA gene. The mutations leading to Tay Sachs disease in India are yet unknown. We aimed to determine mutations leading
to TSD in India by complete sequencing of the HEXA gene. The clinical inclusion criteria included neuroregression, seizures,
exaggerated startle reflex, macrocephaly, cherry red spot on fundus examination and spasticity. Neuroimaging criteria
included thalamic hyperdensities on CT scan/T1W images of MRI of the brain. Biochemical criteria included deficiency of
hexosaminidase A (less than 2% of total hexosaminidase activity for infantile patients). Total leukocyte hexosaminidase
activity was assayed by 4-methylumbelliferyl-N-acetyl-b-D-glucosamine lysis and hexosaminidase A activity was assayed by
heat inactivation method and 4-methylumbelliferyl-N-acetyl-b-D-glucosamine-6-sulphate lysis method. The exons and
exon-intron boundaries of the HEXA gene were bidirectionally sequenced using an automated sequencer. Mutations were
confirmed in parents and looked up in public databases. In silico analysis for mutations was carried out using SIFT,
Polyphen2, MutationT@ster and Accelrys Discovery Studio softwares. Fifteen families were included in the study. We
identified six novel missense mutations, c.340 G.A (p.E114K), c.964 G.A (p.D322N), c.964 G.T (p.D322Y), c.1178C.G
(p.R393P) and c.1385A.T (p.E462V), c.1432 G.A (p.G478R) and two previously reported mutations. c.1277_1278insTATC
and c.508C.T (p.R170W). The mutation p.E462V was found in six unrelated families from Gujarat indicating a founder effect.
A previously known splice site mutation c.805+1G .C and another intronic mutation c.672+30 T.G of unknown
significance were also identified. Mutations could not be identified in one family. We conclude that TSD patients from
Gujarat should be screened for the common mutation p.E462V.
Citation: Mistri M, Tamhankar PM, Sheth F, Sanghavi D, Kondurkar P, et al. (2012) Identification of Novel Mutations in HEXA Gene in Children Affected with Tay
Sachs Disease from India. PLoS ONE 7(6): e39122. doi:10.1371/journal.pone.0039122
Editor: Markus Schuelke, Charite ´ Universita ¨tsmedizin Berlin, NeuroCure Clinical Research Center, Germany
Received October 8, 2011; Accepted May 16, 2012; Published June 18, 2012
Copyright:  2012 Mistri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work at FRIGE was supported by grant from Indian council of medical research (ICMR), project no BMS: 54/2010. The work at Genetic Research
Center, NIRRH (National Institute for Research in Reproductive Health) was supported by intramural funds. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jshethad1@gmail.com (JS); tamhankarp@nirrh.res.in (PMT)
. These authors contributed equally to this work.
Introduction
Tay Sachs disease (TSD) (MIM# 272800) is an autosomal
recessive neurodegenerative disorder due to b-hexosaminidase A
deficiency caused by mutation in the HEXA gene (MIM* 606869)
encoding the a subunit of hexosaminidase A, a lysosomal enzyme
composed of a and b polypeptides [1]. The clinical picture ranges
from the acute infantile form rapidly leading to death to
progressive later onset form compatible with a longer survival.
Clinical features include neuroregression, generalized hypotonia,
exaggerated startle response and cherry-red spot seen on fundus
examination. Affected patients have deficient enzyme activity of
Hexoasaminidase A (Hex A) in leukocytes or plasma [2]. The
human HEXA gene is located on chromosome 15 q23-q24 with 14
exons. Nearly 130 mutations have been reported so far in the
HEXA gene to cause TSD and its variants, including single base
substitutions, small deletion, duplications and insertions splicing
alterations, complex gene rearrangement and partial large
duplications (http://www.hgmd.cf.ac.uk/). Most of these muta-
tions are private mutations and have been present in a single or
few families. Only few mutations have been commonly found in
particular ethnicities or geographically isolated populations. In the
Ashkenazi Jews, 94 to 98% patients are caused by one of the three
common mutations c.1277_1278insTATC, c.1421+1G .C and
c.805 G.A (p.G269S) [3–5]. Among the non-Ashkenazi TSD
patients the mutations pattern is completely different. A 7.6 kb
deletion which includes the entire exon 1 and parts of the flanking
sequence, is the major mutation causing TSD in the French
Canadian population [4]. The mutation c.571–1 G.T accounts
for 80% of mutant alleles among Japanese patients with TSD [1].
The c.1277_1278insTATC and the c.805 G.A(p.G269S) muta-
tions are also commonly found in non-Ashkenazi Jewish
populations, along with an intron 9 splice site mutation
(c.1073+1G .A) and the 7.6 kb French Canadian deletion. About
35% of non-Jewish individuals carry one of the two pseudodefi-
ciency alleles; c.739C.T (p.R247W) and c.745C.T (p.R249W),
which are not associated with neurological manifestations, since
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Tay Sachs Disease India
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39122Figure 1. (a) – (e): Sequence Chromatogram of mutations Fig. 1a: c. 340 G.A (p.E114K)(homozygous); Fig. 1b: c.508C.T (p.R170W)(homozygous);
Fig. 1c: c.964 G.A (p.D322N)(homozygous); Fig. 1d: c.964 G.T (p.D322Y)(heterozygous); Fig. 1e: c.1178 G.C (p.R393P) (homozygous); Fig. 1f:
c.1385A.T (p.E462V) (homozygous); Fig. 1g: c.1432 G.A (p.G478R)(heterozygous); Fig. 1h: c.672+30T.G (heterozygous); Fig. 1e: c.805+1G .C.
doi:10.1371/journal.pone.0039122.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39122their presence causes the reduction of Hex A activity only towards
the artificial substrate but not to the natural GM2 ganglioside [6].
The mutations responsible for TSD in Indian patients are hitherto
unpublished.
Results
Fifteen families were included in the study. Consanguinity in
parents was present in 4/15 (26.7%) families. The mean age at
presentation was 16.6 months (+/25.4). All patients had seizures,
neuroregression, exaggerated startle reflex, cherry red spot on
fundoscopy, axial hypotonia, increased peripheral limb tone and
brisk deep tendon reflexes. None of the patients had hepato-
splenomegaly. Neuroimaging in form of computed tomography
(CT scan) or magnetic resonance imaging (MRI) of the brain of
the proband was available in 10/13 patients and showed
characteristic findings of putaminal hyperintensity and thalamic
hypointensity in CT scan or T2 weighted images of MRI of the
brain. There were no white matter abnormalities. Significant
deficiency of Hex A activity was observed in the leukocytes of all
thirteen patients and only carrier detection (% Hex A) could be
performed in two families where the proband was not alive
(Table 1).
The DNA of fourteen such affected TSD families did not have
the common mutations c.1277_1278insTATC, c.1421+1G .C,
c.805 G.A (p.G269S), 7.6 kb deletion or the two pseudodefi-
ciency mutations c.739C.T (p.R247W) and c.745C.T
(p.R249W). The common mutation c.1277_1278insTATC was
detected by screening in one family and was confirmed by
sequencing. Complete sequencing analysis revealed nine different
mutations in thirteen families and could not identify any mutation
in one family. We identified six novel deleterious missense
mutations, c.340 G.A, c.964 G.A, c.964 G.T, c.1178C.G
and c.1385A.T, c.1432 G.A, that resulted in amino acid
changes p.E114K, p.D322N, p.D322Y, p.R393P, p.E462V,
p.G478R [refer to Figure 1(a)–(d)]. We also identified known
pathogenic mutations c.508C.T (p.R170W), c.805+1G .C and
another intronic variant c.672+30T.G of undetermined signifi-
cance (refer to Table 1). The novel mutations were not found in
100 control individuals. The missense mutations were not found in
the 1000 Genome Project. The intronic variant c.672+30T.G
(rs117160567) was found in 1000 Genome Project (Minor Allele
Frequency/Minor Allele Count: C=0.09/20). The mutation
c.1385A.T (p.E462V) was found in the homozygous state in six
acute infantile TSD patients belonging to unrelated families with
common ethnicity (from Gujarat) indicating a founder effect.
Haplotype analysis was performed by sequencing the introns 1, 5,
12, 13 and a 417 basepair region 39 to HEXA gene which
contained several polymorphic markers, in all TSD patients and
30 ethnic controls. Table 2 reveals the haplotypes unique to the
Table 2. Haplotype analysis of founder mutation p.E462V in Gujarati patients with Tay Sachs disease.
39 to HEXA
gene(a) Al Intron 13 (b) Al Intron 12 (c) Al Intron 5 (d) Al Intron 1 (e) Al
rs35949555 T rs12904378 C rs74020947 G rs191809305 A rs191094610 A
rs11629508 C rs113387077 A rs57733983 T rs188570040 T rs188410016 C
rs76075374 C rs2912217 G rs189856670 A rs60920713 C rs186683578 A
rs60288568 G rs190224431 G rs140288703 G rs59427837 C rs184065715 T
rs112626309 G rs145393752 T rs185764548 C rs12910617 C rs78629973 C
rs3087652 T rs112806142 G rs111680766 A rs12593333 A rs4470105 C
rs890313 G rs147324677 C rs12592727 T rs78278321 G
rs111827252 C rs113941121 A rs4776594 G rs76530364 T
rs75015614 T rs34085965 A rs75756977 C
rs62022857 C rs2303448 C rs75981720 C
rs118002327 C rs76941148 C
rs2912218 T rs80039124 T
rs113665670 CTCT rs78970750 A
rs149948017 T rs76950885 C
rs4777502 C rs74738827 A
rs147502219 T rs80238386 G
rs140091006 G rs77154656 C
rs145012038 C rs78097627 C
rs149092488 G rs77511366 A
rs74325922 G
rs74787391 C
(Al = allele).
Region (a) =417 bp region 39 to HEXA gene (chromosome 15 plus strand: 72635626 to 72636042); region (b) =405 bp region in intron 13 of HEXA gene (chromosome
15 plus strand: 72637019 to 72637423; and 567 bp region in intron 13 of HEXA gene (chromosome 15 plus strand: 72637428 to 72637994; region (c) =489 bp region in
intron 12 of HEXA gene (chromosome 15 plus strand:72638306 to 72638794); region (d) =424 bp region in intron 5 of HEXA gene (chromosome 15 plus strand:
72639456 to 72639879); region (e) =405 bp region in intron 1 of HEXA gene (chromosome 15 plus strand: 72656546 to 72656950 and 461 bp region in intron 1 of
HEXA gene chromosome 15 plus strand: 72659130 to 72659590). The chromosome.
coordinates are as per Human Genome Assembly Feb 2009 (GRCh37/hg19).
doi:10.1371/journal.pone.0039122.t002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39122founder mutation and not found in other patients and 30 ethnic
controls. The founder mutation was screened in 500 individuals
using ARMS–PCR (amplification refractory mutation system-
polymerase chain reaction) and two individuals were found to be
carrier for this mutation leading to an allele frequency of 1/500.
The ARMS method used the primers.
59-CCAGGTTTGTGTTGTCCACATATT-39 (mutation spe-
cific primer) and 59-AGTTACCCCACCATCACCAGACTG-39
(common forward primer) in a PCR reaction to show presence of
p.E462V allele (123 base pair PCR product) and the primers 59-
CCAGGTTTGTGTTGTCCACATATA-39 (wild type specific
primer) and the common forward primer in another PCR reaction
to show presence of wild type allele (123 base pair PCR product).
Carriers were confirmed by sequencing.
The Sorting Tolerant from Intolerant (SIFT) index (available at
http://sift.jcvi.org/), Polyphen2 scores (available at http://
genetics.bwh.harvard.edu/pph2/) and MutationT@ster (available
at http://www.mutationtaster.org/) scores for the non-synony-
mous single nucleotide substitutions are given in Table 3. [7–9]
The predictions of the SIFT, Polyphen2 and MutationT@ster
algorithms were in concordance with the observed pathogenicity
in case of mutations p.E114K, p.R170W, p.D322N, p.D322Y,
and p.E462V. The RMSD (Root mean square deviation) values
for the modeled mutants were significant for pathogenicity for all
missense mutations except p.E114K (refer to Table 3 and
Figure 2). This mutation was determined pathogenic by SIFT
and Polyphen analysis. The docking studies reveal that the
residues aAsp322, aTyr421, aArg178, aGlu462 play a crucial role
in the binding and orientation of GalNAc (refer to Figure 3 and
Tables 3, 4 and 5).
The intronic mutation c.672+30T.G was evaluated for
pathogenicity using MutationT@ster. The mutation was predicted
to lead to gain of aberrant donor splice site at position c.672+35
(score 0.5). However no functional studies could be carried out
further since the family was not available later for further testing. It
was not found in 100 controls with normal Hex A values. Another
intronic mutation c.805+1G .C disrupts the normal donor splice
site of the intron 7. This was found in a consanguineous carrier
couple from Andhra Pradesh with history of a previous child being
affected with Tay Sachs disease (refer to Table 1).
Discussion
The clinical and neuroimaging features of infantile Tay Sachs
disease seen in our patients were consistent with the defined
phenotype. The results of enzyme activity measurements (Hex A
expressed as percentage of total Hex activity) varied from 0% to
1.29%. This is consistent with previous observations that infantile
TSD patients have values ranging from 0 to 2% [10]. Recent
studies in patients from India have revealed similar values in
infantile TSD patients [11]. Our study indicates that the known
deleterious common mutations c.1278insTATC, c.1421+1G .C,
c.805 G.A (p.G269S), 7.6 kb deletion and the two pseudodefi-
ciency mutations c.739C.T (R247W) and c.745C.T (R249W)
are not common in Indian TSD patients.
We found three novel deleterious mutations (p.D322N,
p.D322Y, p.E462V) occurring at the functionally active site of
the alpha subunit of hexosaminidase A. The mutation p.R393X
has been previously identified in infantile TSD patients from
Persia, Turkey and Iraq populations [12–14]. The mutation
p.E114K is proximal to the N-glycosylation site a-N115.
We were especially interested in analyzing the c.1385 T.A
(p.E462V) mutation because it was identified in six unrelated
families from one ethnic group but, to our knowledge, has never
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39122been identified in TSD patients of other ethnic origin. The
sequence alignment of Hex A from various species (refer to
Figure 4) reveal that the residue E462 is highly conserved. The
RMSD of the modeled mutant is also significantly higher as
compared to the wild-type protein (refer to Table 1 and Figure 2).
This mutation was present in homozygous state in all six patients
exhibiting infantile TSD. This is in accordance with previous
observations that missense mutations responsible for infantile TSD
were generally located in a functionally importance region, such as
the active site and the dimer interface [15].
The mutation c.508C.T (p.R170W) has been previously
reported in different ethnic groups [Japanese, French-Canadian
(Estree region, Quebec) and Italian patients] [16–18]. The side
chain of R170 in domain II forms a hydrogen bond with the E141
in domain I. The substitution of R with W with a bulkier side
chain has a large effect on the interface of domains I and II. This
would destabilize the domain interface and cause degradation of
the a-subunit [16], [19].
The intronic mutation c.672+30T.G has been previously
reported in an obligate carrier individual detected on biochemical
screening. The mutation has been reported to be benign in this
paper as it was found in combination with another disease causing
mutation in an obligate carrier [20]. The National Center for
Biotechnology Information (NCBI) single nucleotide polymorphism
database (dbSNP) (http://www.ncbi.nlm.nih.gov/SNP/index.
html) revealed that the minor allele count of this polymorphism
(rs117160567) is minimal (C=0.0103/13). However this allele has
not been reported in homozygous state till date. Thus, the
pathogenic potential of this mutation remains to be explored by
functional analysis. The presence of another HEXA mutation in this
patientinformoflargeheterozygousdeletionormutationinregions
not analyzed like deep intronic and promoter cannot be ruled out.
The splice site mutation c.805+1G .C has been reported
previously from Portuguese patients [21]. Another substitution at
the same nucleotide c.805+1G .A is common in French-Canadian
patients from the Quebec region in Canada [22]. Both mutations
are known to be associated with the infantile form of TSD.
In one of our patients, no mutation could be identified.
Complete gene sequencing strategy is likely to miss large
heterozygous deletions or gene rearrangements. Southern blot
analysis or multiplex ligase dependent probe amplification (MLPA)
based methods to detect these changes were not available to us.
A large number of gene mutations causing TSD have been
previously reported in the HEXA mutation database http://www.
hexdb.mcgill.ca/. Among them, mutations resulting in gross
alterations in the Hex a-subunit sequence are generally found in
the severe infantile form. However, missense mutations causing
amino acid substitutions have been found in both the infantile and
late onset phenotypes [23]. Mahuran et al, (1999) reported that the
detrimental effect of most mutations is on overall folding and/or
transport of the protein rather than on the functional sites [24].
Some of the mutations identified in our series affect crucial active
residues or cause significant structural aberrations leading to the
infantile form of the disease.
Conclusion
The mutations responsible for Tay Sachs disease in Indian
population are unique. Patients originating from Gujarat state
Figure 2. Superimposed native structures (blue) and mutant structure (brown) of the a subunit produced using Accelrys Discovery
Studio software from top left clockwise: a) mutation p.E114K causes conformational change, b) p.R170W disrupts the beta sheet c) p.D322N
affects the active catalytic site, d) p.R393P causes conformational change, e) p.E462V affects the active site and the dimerization of alpha-beta
subunits, f) p.G478R disrupts the alpha helix.
doi:10.1371/journal.pone.0039122.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39122could be screened for the founder mutation p.E462V. Except for
this mutation, the rest of the mutations were non-recurrent.
However, screening for the above mutations would be recom-
mended for cost effective testing of TSD patients.
Methods
Ethics Statement
The study protocol was approved by Ethics Committee of
Foundation for Research in Genetics and Endocrinology,
Ahmedabad, Gujarat (Reg No- E/13237).
Study Subjects
Clinical details were noted in a case record form and an
informed written consent was obtained from each family. The
clinical criteria for inclusion in this study was history of
neuroregression, exaggerated startle reflex, cherry red spots on
fundus examination and relative macrocephaly. Neuroimaging
criteria included presence of gray matter disease shown by
hyperintensity in basal ganglia and/or hypointensity in thalamus
in T2 weighted images of MRI of the brain. Five ml peripheral
blood was collected from the patients for leukocyte enzyme assay
and DNA extraction. Leukocyte hexosaminidase A activity was
Figure 3. Stereoscopic view of the docking experiments. Green sticks indicate C
a trace of amino acids involved in the active site and CPK
(Corey-Pauling-Koltun) coloring scheme represents ligand GalNAc (N acetyl galactosamine) portion of GM2 ganglioside. Fig 4a: Wild type (aHex-A-
GalNAc complex). Fig 4b: Mutant (aD322N-GalNAc), Red shows mutation p.D322N, Fig 4c: Mutant (aD322Y-GalNAc), Cyan shows mutation p.D322Y,
Fig. 4d: Mutant (a E462V-GalNAc), yellow shows mutation p.E462Y.
doi:10.1371/journal.pone.0039122.g003
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minidase (Hex) was measured from the hydrolysis of the synthetic
substrate 4-methylumbelliferyl-N-acetyl-b-D-glucosamine (MUG),
which releases fluorescent 4-methylumbelliferone when acted
upon by b-hexosaminidase. Hexosaminidase B (Hex B) was
determined as the activity left after samples were heated for three
hours at 50uC. This procedure led to loss of Hex A which is heat-
labile but not of hexosaminidase B (Hex B) or intermediate
isoenzyme. Therefore, Hex A activity was obtained after
subtracting Hex B activity from total Hex activity. Hex A was
also assayed with the more specific sulphated substrate 4-
methylumbelliferyl-N-acetyl-b-D-glucosamine-6-sulphate (MUGS)
[25]. Hex A activity (obtained from MUGS lysis) was expressed as
percentage of total Hex activity (obtained from MUG lysis).
Screening Procedure for Common Mutations
Genomic DNA was extracted by the standard salting out
method. Primary screening of the common mutations
c.1277_1278insTATC, c.1421+1G .C, 7.6 kb deletion, the
pseudo-deficiency alleles (p.R247W and p.R249W) was performed
by amplification refractory mutation system – polymerase chain
reaction (ARMS PCR) using normal and mutant primers as a
reverse primers and common forward primers as previously
described [26], [27]. PCR amplification was performed for each
mutation separately in a 15 ul final reaction volume containing
500 ng genomic DNA, 106 Cetus buffer, 2.0 mM dNTPs, 1 U
Taq polymerase, 4–6 pmol of each primers and 1.5 ml1 0 6Cetus
buffer. The thermocycling conditions were 10 min at 94uC,
followed by 25–32 cycles of amplification consisting 30 s–60 s at
94uC, 30 s–60 s at 55–63uC and 30 s –3 min at 72uC, and a final
elongation for 10 min at 72uC and PCR product were run on 2%
agarose and visualized under ultraviolet transilluminator.
Molecular Analysis of HEXA Gene
The exonic and intronic flanking sequence of the HEXA gene
were PCR amplified in 14 fragments using previously described
primers [28]. DNA amplification was performed for each fragment
in a 10 ml final volume containing 100 ng genomic DNA, 1 mM
dNTPs, 10 pmol of each primer, 1 U Taq polymerase and 1 ml
10 X PCR buffer. Thirty cycles of amplification were used, each
consisting 1 min denaturation at 94uC, 45 s annealing at 60–65uC
suitable for each exons and 45 s extension at 72uC in a thermal
cycler. Final extension time was 10 minutes. Negative control PCR
tubes contained all of the above ingredients except DNA. PCR
products were then electrophoresed in 2% agarose along with the
appropriate negative controls and a 100 base-pair DNA ladder.
Products that passed this quality check were purified by treatment
with Exo-SAP-IT
TM (USB Corporation, OH, USA) and then
sequenced using BigDye Terminator v3.1 and capillary electro-
phoresis was performed using an automated sequencer ABI-3130
(Applied Biosystems, CA, USA). Mutations were described
according to mutation nomenclature, considering nucleotide +1
the A of the first ATG translation intitiation codon. Nucleotide
numbers are derived from cDNA HEXA sequence (RefSeq cDNA
NM_000520.4). Putative mutations were confirmed in two
separate PCR products from the patient’s DNA. Heterozygosity
for these mutations was confirmed in the parents. The mutations
identified were then looked up in public databases like The
Human Gene Mutation Database (http://www.hgmd.cf.ac.uk),
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/index.html) and
McGill University database (http://www.hexdb.mcgill.ca). Novel
variants were also ruled out as polymorphism by sequencing the
corresponding exons/introns in 100 normal unrelated individuals.
In Silico Analysis
Prediction of functional effects of non-synonymous single
nucleotide substitutions (nsSNPs) was done using softwares SIFT
(Sorting Intolerant From Tolerant) (available at http://sift.jcvi.
org/), Polyphen2 (Polymorphism Phenotyping v2) (available at
http://genetics.bwh.harvard.edu/pph2/) and MutationT@ster
(available at http://www.mutationtaster.org/). [7–9] HumVar-
trained prediction model of Polyphen2 was used for distinguishing
mutations with drastic effects from all the remaining human
variation, including abundant mildly deleterious alleles. Evolu-
tionary conservation of the amino acid residues of Hex A was
analyzed using ClustalW program available online at http://www.
uniprot.org/help/sequence-alignments.
Structural Studies
Protein Preparation. The mutants (aD322N, aD322Y,
aE462V )were built using build mutant protocol of Accelrys
Discovery studio 2.0 using the crystallographic structure of Hex A
Table 4. Hydrogen bond interaction for the wild type and
Mutant complexes.
Complex
Protein
(Residue:Atom) Ligand Atom
Wild Type-GalNAc ARG178:HH12 O2
ARG178:HH22 O2
TYR421:HH O6
TRP460:HE1 O6
ASP207:OD1 H26
GLU323:OE1 H28
GLU462:OE2 H29
HIS262:NE2 H30
ASP322:OD2 H20
aD322N-GalNAc ARG178:HH22 O1
GLU462:OE2 H26
HIS262:NE2 H29
aD322Y-GalNAc ARG178:HH22 O1
GLU462:OE2 H26
GLU323:OE2 H28
GLU462:OE2 H29
aE462V-GalNAc ARG424:HH21 O6
GLU323:OE2 H27
GLU323:OE1 H28
doi:10.1371/journal.pone.0039122.t004
Table 5. Ligand Binding Energy Details for wildtype and
mutant a subunits.
Complex
Binding Energy (kcal/
mol) Complex
Wild Type-GalNAc 2115.94 Wild Type-GalNAc
aD322N-GalNAc 238.87 aD322N-GalNAc
aD322Y-GalNAc 252.22 aD322Y-GalNAc
aE462V-GalNAc 280.88 aE462V-GalNAc
doi:10.1371/journal.pone.0039122.t005
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mutants were energy minimized using CHARMm forcefield and
200 cycles of steepest descent algorithm.
Ligand Preparation. The structural coordinates of GM2
ganglioside was retrieved from the PubChem database (CID
9898635). The GalNAc (N-acetyl galactosamine) portion of the
GM2 ganglioside was considered for docking on the active site of
Hex A as reported previously [29]. It was prepared using the
Prepare Ligands protocol of Accelrys Discovery studio 2.0.
Molecular Docking. Structural analysis revealed that resi-
dues R178, D207, H262, E323, D322, W373, W392, Y421, N423,
R424 and E462 constitute the active site of aHex-A. This
information was used to define the binding site and docking studies
were performed using the LigandFit protocol of Accelrys
Discovery studio 2.0. The potential energy and Root Mean
Figure 4. Multiple protein sequence alignment using ClustalW shows evolutionary conservation of amino acid residues. Fig. 3a:
aE114 and aR170; Fig. 3b: aD322 and aR393; Fig. 3c: aE462 and aG478.
doi:10.1371/journal.pone.0039122.g004
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39122Square Deviations (RMSD) of the mutant structures with respect
to the wild-type structure were calculated. RMSD values more
than 0.15 were considered as significant structural perturbations
that could have functional implications for the protein [15].
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